Education
About Us
Working with TipRanks
Follow Us
Heron Therapeutics (HRTX)
NASDAQ:HRTX
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.01Last Year’s EPS
-0.06Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 06, 2025
|% Change Since: -3.76%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Positive
The call highlighted strong financial performance, significant growth in key product segments, and successful strategic initiatives, despite ongoing market competition and operational challenges in onboarding new accounts.Company Guidance
During the Heron Therapeutics Q1 2025 earnings call, the company reported total net revenues of approximately $39 million, achieving a record quarterly adjusted EBITDA of $6.2 million and a net income of $2.6 million. The oncology franchise, including CINVANTI and SUSTOL, generated combined net revenues of $28.6 million, despite a competitive market. Heron's gross profit margin for the quarter was 78%, attributed to production efficiencies and increased sales volumes. G&A expenses decreased to $25 million from the previous year, while research and development expenses were reduced to $2.3 million. The company revised its adjusted EBITDA guidance range to $4 million to $12 million, up from the previous range of $0 to $8 million. Heron emphasized its focus on disciplined execution and optimizing commercial performance, particularly for its key products ZYNRELEF and APONVIE, which saw significant growth in Q1 2025.Significant Revenue Growth
Heron Therapeutics generated total net revenues of approximately $39 million for Q1 2025, with a record quarterly adjusted EBITDA of $6.2 million and net income of $2.6 million, highlighting a strong financial performance.
Oncology Franchise Success
Combined net revenues from CINVANTI and SUSTOL reached $28.6 million for the quarter, maintaining market share in a competitive environment and demonstrating strong product performance.
Strong Product Growth in Acute Hospital Segment
APONVIE and ZYN experienced significant growth in Q1 2025, up over 432% and 60%, respectively, compared to the same period last year, indicating strong market adoption.
Improved Financial Metrics
Product gross profit for Q1 2025 was $30.4 million or 78%, an increase from 76% in the same period in 2024, due to production efficiencies.
Revised Positive Financial Guidance
The company revised its adjusted EBITDA guidance from a range of $0 to $8 million to a range of $4 million to $12 million.
---
HRTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
HRTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2025 | $2.13 | $2.42 | +13.62% |
Feb 27, 2025 | $1.71 | $2.05 | +19.88% |
Nov 12, 2024 | $1.84 | $1.28 | -30.43% |
Aug 06, 2024 | $2.67 | $2.00 | -25.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Heron Therapeutics (HRTX) report earnings?
Heron Therapeutics (HRTX) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Heron Therapeutics (HRTX) earnings time?
Heron Therapeutics (HRTX) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HRTX EPS forecast?
HRTX EPS forecast for the fiscal quarter 2025 (Q2) is -0.01.
---
